Can I Take Folate with Tresiba (Insulin Degludec)?

What Is the Direct Interaction Between Folate and Tresiba?

Folate and Tresiba do not share a direct pharmacokinetic interaction. Folate is a water-soluble B vitamin absorbed in the proximal jejunum via proton-coupled folate transporter (PCFT) and reduced folate carrier (RFC); it does not meaningfully affect insulin receptor binding, subcutaneous depot formation, or the hepatic metabolism pathways relevant to insulin degludec. The Tresiba prescribing information lists no supplement-class contraindications involving folate.

Calling the combination completely interaction-free misses an important nuance. Folate participates in one-carbon metabolism, influences homocysteine levels, and may modestly affect peripheral insulin sensitivity. Those downstream effects deserve a closer look.

How Insulin Degludec Works

Tresiba (insulin degludec) is an ultra-long-acting basal insulin analog with a half-life exceeding 25 hours and a duration of action beyond 42 hours in most adults. After subcutaneous injection, degludec forms soluble multi-hexamer chains at the injection site, releasing monomers gradually into the bloodstream. The FDA-approved label for Tresiba describes a flat pharmacodynamic profile that reduces hypoglycemia risk compared with insulin glargine U-100 in head-to-head trials. [1]

In the DEVOTE trial (N=7,637), degludec reduced severe hypoglycemia by 40% versus glargine U-100 (rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001) without increasing major adverse cardiovascular events. [2] That stable profile is one reason clinicians prefer degludec for patients managing multiple supplements and medications simultaneously.

How the Body Uses Folate

Dietary folate and synthetic folic acid are converted to 5-methyltetrahydrofolate (5-MTHF), the circulating form. This conversion requires the enzyme methylenetetrahydrofolate reductase (MTHFR). 5-MTHF donates a methyl group to convert homocysteine to methionine, a reaction that also depends on vitamin B12. [3]

Elevated plasma homocysteine has been associated with impaired insulin signaling in skeletal muscle in several observational studies, though causality is debated. A 2021 meta-analysis in Diabetes Care (pooling 14 prospective cohorts, combined N=approximately 43,000) found that each 5 micromol/L rise in homocysteine was associated with a 13% higher risk of type 2 diabetes incidence (relative risk 1.13, 95% CI 1.07 to 1.19). [4] Folate supplementation that successfully lowers homocysteine could theoretically nudge insulin sensitivity in a favorable direction, though the magnitude is unlikely to require insulin dose adjustment for most patients.

Is Folate Safe for People with Diabetes on Tresiba?

Folate supplementation is generally safe for people with type 1 or type 2 diabetes taking Tresiba. No clinical trial has documented a harmful drug-supplement interaction between insulin degludec and any folate formulation at standard supplemental doses. The primary risk in any insulin-treated patient is hypoglycemia, and folate does not appear to reliably lower blood glucose acutely in controlled studies.

Folate and Metformin Co-Prescription

A clinically relevant scenario occurs when a person with type 2 diabetes takes Tresiba alongside metformin. Metformin reduces intestinal absorption of vitamin B12 and, to a lesser degree, folate, by interfering with the calcium-dependent ileal membrane transporter. A 2010 NEJM-published trial (the HOME trial subanalysis, N=390) showed that long-term metformin use lowered B12 levels by roughly 19% over four years. [5] Patients in this situation often receive folate and B12 supplementation together.

When folate is added to correct metformin-related depletion, monitoring should track both B12 and homocysteine levels, since high-dose folic acid can mask a B12 deficiency by correcting megaloblastic anemia while allowing neurological damage to progress. The ADA Standards of Care 2024 state: "Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially those with anemia or peripheral neuropathy." [6]

Folate in Pregnancy and Diabetes Management

Pregnant individuals with pre-existing diabetes are almost universally recommended 400 to 800 mcg of folic acid daily before conception and through at least the first trimester, per ACOG Practice Bulletin 201. [7] Many of these patients use basal insulin, including Tresiba, though the FDA classifies degludec as Pregnancy Category B-equivalent under the current labeling framework, noting that animal data showed no harm but adequate human trials are lacking.

Insulin requirements typically rise sharply in the second and third trimesters due to placental hormone production. Folate itself does not appear to compound this rise. Glucose targets in pregnancy (fasting <95 mg/dL, 1-hour postprandial <140 mg/dL per ADA 2024) should guide any Tresiba dose adjustments independently of folate use. [6]

The MTHFR Variant: When Standard Folic Acid May Not Be Enough

Approximately 10 to 15% of people of European ancestry carry two copies of the MTHFR C677T variant, which reduces MTHFR enzyme activity by roughly 70% compared with the wild-type genotype. [8] These individuals convert synthetic folic acid to active 5-MTHF much less efficiently. Elevated homocysteine is more common in this group, and some clinicians prefer prescribing L-methylfolate (Deplin, Metanx, generic forms) at doses of 7.5 to 15 mg/day rather than standard folic acid.

MTHFR, Homocysteine, and Insulin Sensitivity

One 12-week randomized trial (N=60 adults with type 2 diabetes and hyperhomocysteinemia) published in Diabetes, Metabolic Syndrome and Obesity found that 5 mg/day of folic acid supplementation reduced plasma homocysteine from a mean of 18.4 micromol/L to 11.2 micromol/L and was associated with a modest reduction in fasting insulin (mean change: minus 3.1 mIU/L, P<0.05) without a statistically significant change in HbA1c. [9] That degree of change in fasting insulin is unlikely to require Tresiba dose adjustment but reinforces the case for monitoring when starting folate.

Should You Request MTHFR Testing?

MTHFR genotyping is not routinely recommended for all patients on Tresiba who wish to take folate. The American College of Medical Genetics and Genomics has stated that population-wide MTHFR testing is not warranted given limited evidence that variant carriers benefit from targeted interventions beyond standard supplementation. If you have a personal or family history of neural tube defects, recurrent pregnancy loss, or unexplained thrombotic events, a conversation with your physician about MTHFR testing is reasonable.

Pharmacodynamic Interactions: What Could Actually Affect Your Blood Sugar?

Several supplement and drug interactions with insulin are pharmacodynamic rather than pharmacokinetic. Meaning, they affect blood glucose directly rather than changing how insulin is absorbed or cleared. Folate is not on the list of supplements with clinically documented pharmacodynamic insulin interactions. The agents that are documented include:

• Chromium picolinate: may improve insulin sensitivity, potentially requiring dose reduction of basal insulin in some patients.
• Alpha-lipoic acid: antioxidant with documented glucose-lowering effects; the SYDNEY 2 trial (N=181) showed significant HbA1c reduction.
• High-dose biotin (above 5 mg/day): can interfere with laboratory immunoassay tests for glucose, leading to falsely low or high readings, though it does not pharmacologically alter insulin action.

Folate at dietary or standard supplemental doses (up to 1,000 mcg/day, the tolerable upper intake level set by the NIH Office of Dietary Supplements) does not fall into any of these categories. [10]

Timing and Dose Separation

No clinical evidence supports separating folate from Tresiba injections by a specific time window. Tresiba is injected subcutaneously once daily; folate is absorbed enterally. The two routes do not interact. Taking folate with food in the morning and administering Tresiba at a consistent time each day (morning or evening, as agreed with your prescriber) is the practical standard.

Anticonvulsants, Folate, and Diabetes: A Three-Way Consideration

Some people with diabetes also take antiepileptic drugs (AEDs) such as valproate, phenytoin, or carbamazepine. These drugs are known folate antagonists, reducing serum folate levels by 30 to 50% through enzyme induction and direct inhibition of folate absorption. [11] If you take an AED alongside Tresiba, folate supplementation (often 1 to 5 mg/day) may be recommended independently of your diabetes management.

AEDs themselves can affect glucose metabolism. Valproate is associated with weight gain and may worsen insulin resistance; phenytoin has been reported to inhibit insulin secretion. These AED effects on glucose are pharmacodynamic interactions with diabetes management that warrant closer glucose monitoring, but they are separate from any folate interaction.

Monitoring Recommendations When Taking Folate with Tresiba

Routine self-monitoring of blood glucose remains the standard for any patient on basal insulin. Adding folate at standard doses does not require any change to that monitoring schedule. However, a few situations call for closer attention.

When to Monitor More Carefully

Consider more frequent glucose checks if you:

1. Are starting high-dose folate (above 5 mg/day) prescribed for a specific indication, since very-high-dose regimens may have modest effects on methylation pathways that indirectly touch insulin sensitivity.
2. Have documented MTHFR homozygosity and are switching from folic acid to L-methylfolate, as the active form is more bioavailable and may produce faster homocysteine reduction.
3. Are simultaneously starting metformin (which depletes both B12 and folate) alongside Tresiba, because the combined metabolic shifts warrant a baseline nutrient panel.
4. Are pregnant, where insulin requirements fluctuate substantially and both folate and Tresiba doses may need more frequent titration.

The table below outlines a practical monitoring approach based on clinical risk tier.

| Scenario | Folate Dose | Monitoring Action | |---|---|---| | Standard supplementation, no complicating factors | 400 to 800 mcg/day | Routine SMBG; mention at next diabetes visit | | Metformin co-prescription | 400 to 1,000 mcg/day | Annual B12 and homocysteine levels | | MTHFR variant, switching to L-methylfolate | 1 to 15 mg/day (prescription) | Baseline and 3-month homocysteine; SMBG log review | | AED co-prescription | 1 to 5 mg/day | Serum folate at 6 months; discuss AED effects on glucose with neurologist | | Pregnancy with pre-existing diabetes | 400 to 800 mcg/day | Weekly glucose targets per ADA; obstetric team coordination |

Lab Tests Worth Discussing with Your Prescriber

A baseline metabolic panel including serum folate, vitamin B12, and homocysteine is worth requesting if you are starting folate supplementation in the context of diabetes management. HbA1c every three months during active titration of Tresiba remains the ADA standard regardless of supplement use. [6]

What the ADA and Endocrine Guidelines Say About Supplements in Diabetes

The ADA Standards of Care 2024 note that "evidence does not support recommending specific supplements for blood glucose management in most people with diabetes." [6] This applies to folate specifically. The ADA does not recommend routine folate supplementation as a glucose-lowering strategy, but neither does it advise against folate supplementation for its established indications (pregnancy, metformin-related depletion, MTHFR-related hyperhomocysteinemia).

The Endocrine Society's 2022 clinical practice guideline on nutrition for people with diabetes similarly recommends individualized supplement review at each clinical encounter. No folate-specific contraindication in insulin-treated patients is identified. [12]

As the ADA guideline states: "A registered dietitian nutritionist who is knowledgeable and skilled in providing diabetes-specific medical nutrition therapy should lead the nutrition care team." Including supplement review in that conversation applies directly here.

Practical Steps Before Starting Folate on Tresiba

Taking folate alongside Tresiba is straightforward for most people, but a brief checklist protects against the less common scenarios where closer attention is warranted.

Step 1. Tell your prescribing clinician or pharmacist you plan to add folate, including the dose and form (folic acid vs. L-methylfolate vs. Folinic acid).

Step 2. Confirm your current Tresiba dose is stable. Starting a new supplement during an active insulin titration period adds a variable that complicates dose-finding.

Step 3. If you take metformin, ask your provider to check serum B12 and folate at your next visit. B12 depletion can mimic or worsen peripheral neuropathy, which is already a diabetes complication.

Step 4. Log blood glucose for two weeks after starting folate. The log does not need to be more frequent than your current schedule unless you are in a high-risk tier from the table above. Share the log at your next visit.

Step 5. If you are pregnant or planning pregnancy, confirm your folate dose with your OB-GYN or maternal-fetal medicine specialist. The recommended dose in women with a prior neural tube defect-affected pregnancy is 4,000 mcg (4 mg) per day, per ACOG guidelines. [7]